Funded Biotechnology Startups in United States
11 funded biotechnology startups in united states — recent funding rounds, disclosed amounts, and headquarters. Updated weekly, free to browse.
Recent funding rounds in U.S. biotechnology and pharmaceuticals, drawn from the 11 most recent closes, show activity concentrated between September and November 2025. Ollin Biosciences leads the set with a $100M Series A out of Austin (September 16), an unusually large amount for that stage. The next largest deals are AusperBio's $63M Series B in Foster City and OncoC4's $50M Series B in Rockville, both closing in late September and early October 2025. Series A is the most represented stage across these rounds, accounting for four companies — Bexorg ($23M, San Francisco), AeroRx Therapeutics ($21M, La Jolla), AltrixBio ($5M, Cambridge), and Ollin — with a wide size spread that reflects divergent therapeutic focuses and development timelines.
Geographic concentration is visible at the city level. Cambridge, MA appears twice — Dayra Therapeutics ($20M) and AltrixBio ($5M) — as does La Jolla, CA with AeroRx Therapeutics and Enlaza Therapeutics. Seed-stage activity is sparse; Chirality Biosciences' $3M round in Farmingdale is the only seed deal in this snapshot.
Most recent rounds
11 shownRelated listings
Frequently asked
What are the largest recent funding rounds in U.S. biotech and pharma?
Among the 11 most recent rounds, Ollin Biosciences raised the most at $100M (Series A, Austin, September 2025), followed by AusperBio at $63M (Series B, Foster City) and OncoC4 at $50M (Series B, Rockville). These three deals alone account for the majority of dollar volume in this snapshot.
Which U.S. cities are seeing the most biotech funding activity right now?
Cambridge, MA and La Jolla, CA each appear twice in the most recent 11 rounds — Cambridge with Dayra Therapeutics and AltrixBio, La Jolla with AeroRx Therapeutics and Enlaza Therapeutics. San Francisco, Austin, Foster City, Rockville, Scottsdale, San Diego, and Farmingdale each contribute one company.
What funding stages are most common in recent U.S. biotech rounds?
Series A is the most frequent stage, representing four of the 11 companies — Bexorg, AeroRx Therapeutics, AltrixBio, and Ollin Biosciences. Venture rounds with unspecified series account for three companies (Dayra Therapeutics, Oligon, Enlaza Therapeutics), followed by two Series B deals, one Series C (SelectION, $5M, San Diego), and one Seed (Chirality Biosciences, $3M, Farmingdale).
How wide is the range in Series A deal sizes for this segment?
The four Series A rounds in this dataset range from $5M (AltrixBio, Cambridge) to $100M (Ollin Biosciences, Austin), with Bexorg at $23M and AeroRx Therapeutics at $21M sitting in a more typical band. The $100M Ollin raise is a notable outlier at that stage.
Which companies in this segment have reached Series B or later?
Three companies reflect later-stage financing: OncoC4 (Series B, $50M, Rockville), AusperBio (Series B, $63M, Foster City), and SelectION (Series C, $5M, San Diego). All three rounds closed within a two-week window in late September to early October 2025.
What is the date range covered by the most recent rounds in this segment?
The 11 most recent rounds span September 13, 2025 (Enlaza Therapeutics) through November 26, 2025 (Dayra Therapeutics), a roughly 10-week window. The bulk of activity — nine of the 11 deals — falls within September and October 2025.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.